Angiopoietin-like protein 3 (ANGPTL3) plays an essential role in lipoprotein metabolism. ANGPTL3 inhibits lipoprotein lipase (LPL), that hydrolyzes triglycerides on VLDL, and endothelial lipase (EL) that hydrolyzes phospholipids on HDL. However, whereas its role in ApoB-containing lipoprotein metabolism has been already characterized, the role of ANGPTL3 in HDL metabolism and as a potential pharmacological target has not been fully clarified, yet.
In silico prediction of ANGPTL3-endothelial lipase interaction / L. Montavoci, O. Ben Mariem, S. Saporiti, U. Guerrini, T. Laurenzi, A. Ossoli, L. Palazzolo, L. Calabresi, I. Eberini. ((Intervento presentato al convegno Spring Meeting Giovani Ricercatori SIIA, SIMI, SIPREC, SISA - 2022 tenutosi a Rimini nel 2022.
In silico prediction of ANGPTL3-endothelial lipase interaction
L. MontavociPrimo
;O. Ben MariemSecondo
;S. Saporiti;U. Guerrini;T. Laurenzi;A. Ossoli;L. Palazzolo;L. CalabresiPenultimo
;I. Eberini
Ultimo
2022
Abstract
Angiopoietin-like protein 3 (ANGPTL3) plays an essential role in lipoprotein metabolism. ANGPTL3 inhibits lipoprotein lipase (LPL), that hydrolyzes triglycerides on VLDL, and endothelial lipase (EL) that hydrolyzes phospholipids on HDL. However, whereas its role in ApoB-containing lipoprotein metabolism has been already characterized, the role of ANGPTL3 in HDL metabolism and as a potential pharmacological target has not been fully clarified, yet.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
